Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Quoin Pharmaceuticals logo — Rare Diseases are only rare if you don't live with one.

Quoin Pharmaceuticals

Rare Diseases are only rare if you don't live with one.

Founded 2018 United States Ashburn, United States 5 employees Post-IPO Equity Total: $13.69M Biotechnology, Pharmaceutical

General Information

Company Name Quoin Pharmaceuticals
Founded Year 2018
Location United States Ashburn, United States
Employees 5
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Quoin Pharmaceuticals. To contact Quoin Pharmaceuticals, visit quoinpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Quoin Pharmaceuticals compare?

A PDF of Quoin Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Quoin Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, founded in 2018, is an emerging specialty pharmaceutical company with a focus on developing and commercializing therapeutic products for rare and orphan diseases. The company's innovative pipeline comprises three products that have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others. Quoin Pharmaceuticals aims to establish a sales infrastructure to commercialize its products in both the U.S. and Europe and seeks to enter into strategic licensing partnerships for all other territories. The company is committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin Pharmaceuticals has received a $6.50M Post-IPO Equity investment on 05 March 2024. The company's dedication to finding unique solutions for rare and orphan indications and its commitment to expanding the pipeline of products to address the unmet needs of underserved patient populations make it a compelling prospect for potential investors. To learn more about Quoin Pharmaceuticals, visit their website at www.quoinpharma.com. This company, operating in the Biotechnology and Pharmaceutical industries, is positioning itself as an important player in addressing unmet medical needs in rare disease treatment.

Business keywords: Rare Diseases, Orphan Diseases, Specialty Pharmaceutical Company, Therapeutic Products, Unmet Medical Needs, Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, Pipeline Development, Sales Infrastructure, Licensing Partnerships, Underserved Patient Populations, Chronic Rare Skin Diseases, Strategic Partnerships

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $6.50M -
05 Mar 2024
Post IPO Equity $7.00M -
22 Feb 2023
Post IPO Equity $193.54K -
30 Aug 2022

Quoin Pharmaceuticals Alternatives & Competitors

View All Alternatives
Quoin Pharmaceuticals vs
Scioderm, Inc., an Amicus Therapeutics Company
Scioderm, Inc., an Amicus Therapeutics Company United States

Dedicated to pioneering topical solutions for treating chronic skin diseases.

Series B
2 employees
Biotechnology, Health Care
Quoin Pharmaceuticals vs
Ultragenyx
Ultragenyx United States

Going Beyond Every Day

Post-IPO Equity
1535 employees
Biotechnology, Health Care
Quoin Pharmaceuticals vs
Calliditas Therapeutics
Calliditas Therapeutics Sweden

Pioneering treatments for rare diseases. We harness scientific & commercial expertise to improve the...

Post-IPO Debt
242 employees
Biotechnology, Medical Devices
Compare Quoin Pharmaceuticals vs Calliditas Therapeutics
View all alternatives

FAQ About Quoin Pharmaceuticals

Rare Diseases are only rare if you don't live with one.
Quoin Pharmaceuticals was founded in 2018.
Quoin Pharmaceuticals is headquartered in Ashburn, United States.
Quoin Pharmaceuticals operates in Biotechnology and Pharmaceutical. Its work centres on Rare Diseases, Orphan Diseases, Specialty Pharmaceutical Company and Therapeutic Products.
Quoin Pharmaceuticals has approximately 5 employees.
Quoin Pharmaceuticals has completed 3 funding rounds, raising a total of $13.69M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Quoin Pharmaceuticals include Scioderm, Inc., an Amicus Therapeutics Company, Ultragenyx, Calliditas Therapeutics, RELIEF THERAPEUTICS Holding SA, MediciNova, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Quoin Pharmaceuticals and Scioderm, Inc., an Amicus Therapeutics Company are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Quoin Pharmaceuticals, https://bouncewatch.com/company/quoin-pharmaceuticals, updated 27 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout